Bioequivalence Study of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects

NCT04873570 | Completed Phase 1 DMC

• 1 other identifier: CB-034-MOX(M)-2020
• Study Type: interventional
• Target: 38
• Locations: 1 country
• Sites: 1

Brief Summary

Single oral dose, of test and reference Tablet will be administered to healthy volunteers, after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-points. Blood samples will be taken up to 72.0 hours post-dose.

Conditions

Healthy Individuals; Bioequivalence Study

Keywords

Fluoroquinolone; Moxifloxacin; Bioequivalence; Pakistani Population

Outcome Measures

Primary Outcomes (3)

• maximum plasma concentration

  maximum drug concentration in plasma after dose

  up to 72 hours post dose

• Time to reach maximum plasma concentration

  Time required for the drug to reach maximum plasma concentration

  0 to 72 hours post dose

• AUC

  Area under the time versus plasma drug concentration curve

  0-72 hours

Study Arms (2)

Test Group

EXPERIMENTAL

Subjects will be given one Mofest® 400mg (Moxifloxacin HCl) Tablet (1x400mg) manufactured by SAMI Pharmaceuticals (Pvt.) after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point. Blood samples will be taken up to 72.0 hours post-dose.

Drug: Moxifloxacin 400mg

Reference Group

ACTIVE COMPARATOR

Subjects will be given one Avelox® 400mg (Moxifloxacin HCl) Tablet (1x400mg), manufactured by Bayer HealthCare, after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point. Blood samples will be taken up to 72.0 hours post-dose.

Drug: Moxifloxacin 400mg

Interventions

Moxifloxacin 400mg DRUG

Moxifloxacin 400mg IR tablet

Reference Group; Test Group

Eligibility Criteria

• Age: 18 Years - 55 Years
• Gender Eligibility Details: Pakistani Population
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy subjects aged 18 to 55 years inclusive.
• Subjects with a body mass index (BMI) from 18.5 to 30 kg/m2.
• Subject is able to fast for 14 hours and consume standard meals.
• Subjects who are healthy as determined by routine physical examination, including vital sign monitoring (i.e., blood pressure, heart rate, and temperature), 12-Lead ECG, and safety laboratory analysis (i.e., hematology, blood biochemistry, and urinalysis) or viral serology as determined by the investigator.
• Subjects should have negative urine test for drugs of abuse (morphine \& cannabinoids will be tested) and alcohol breath analysis at screening and prior to each check-in.
• Subjects who are able to, understand and sign the Informed Consent Form for Medical Screening during their screening visit and Participation Informed Consent Form on study check-In day.
• Subject agreed not to consume food or beverages including dairy products, tea, coffee, cola drinks, chocolates containing xanthine derivatives (including caffeine, theobromines, etc.) and/or poppy seeds (Khash khash) within 48 hours prior to drug administration until last blood draw in each study period.
• Subject agreed not to intake prescription drugs (especially amiodarone, carbamazepine, Antacids (aluminum and magnesium hydroxides) NSAIDS, digoxin and Blood thinners such as warfarin, etc.) within 14 days or 5 half-lives (whichever is longer) prior to first dose of study medicine.
• Subject agreed not to intake non-prescription drugs (OTC) within 14 days prior to first dose of study medicine.
• Subject agreed to discontinue vitamins, dietary and herbal supplements within 14 days prior to the first dose of study medication.
• Subject agreed not to consume grapefruit and/or its products within 14 days prior to the start of study.

You may not qualify if:

• Subjects who refused to sign Informed Consent Form.
• Subject not able to take medicine orally.
• Pregnant and lactating females.
• History of smoking ≥3 cigarette/day, alcoholism, and positive test for drug of abuse, heavy pan or gutka user as judged by teeth / mouth inspection.
• Subject has clinically relevant evidence of cardiovascular, gastrointestinal/hepatic, renal, psychiatric, respiratory, urogenital, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, drug hypersensitivity, allergy, endocrine, major surgery or other relevant diseases as revealed by medical history, physical examination, and laboratory assessments which may interfere with the absorption, distribution, metabolism or elimination of drugs or constitute a risk factor when taking study medication.
• Subjects known to be allergic to Moxifloxacin and/or other Quinolones antibiotics
• Subject who has received any other investigational drug within four weeks.
• Subject who has participated in any other clinical trials within 3 months.
• Donation or loss of more than 450 mL of blood within 3 months prior to the screening.
• History of any significant illness in the last four weeks which might confound in the result of the study or post additional risk in administrating Moxifloxacin to the subject.
• Subjects tested positive for syphilis (VDRL) or is known to have serum hepatitis or carrier of the Hepatitis B surface antigen (HBs Ag) or are carriers of antibodies to hepatitis C virus (anti-HCV) or to the human immunodeficiency virus (HIV-1 or HIV-2).

Sponsors & Collaborators

• University of Karachi: lead
• SAMI Pharmaceuticals (Pvt.) Ltd.: collaborator
• Center for Bioequivalence Studies and Clinical Research: collaborator

Study Sites (1)

Center for Bioequivalence Studies and clinical research

Karachi, Sindh, 75270, Pakistan

Location

MeSH Terms

Interventions

Moxifloxacin

Intervention Hierarchy (Ancestors)

Fluoroquinolones; 4-Quinolones; Quinolones; Quinolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Prof. Dr. Muhammad R Shah, PhD

  CBSCR, ICCBS, University of Karachi, Pakistan

  PRINCIPAL INVESTIGATOR

• Dr. Naghma Hashmi (Co-PI), PhD

  CBSCR, ICCBS, University of Karachi, Pakistan

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: A single center, open label, randomized, single-dose, two-period, two-way cross-over study

Study Record Dates

• First Submitted: April 28, 2021
• First Posted: May 5, 2021
• Study Start: May 28, 2021
• Primary Completion: June 8, 2021
• Study Completion: June 10, 2021
• Last Updated: September 7, 2022

Record last verified: 2022-09

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)